Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mesenchymal stem cell therapy for neurological disorders - Medipost

Next Previous
Search
Drug Profile

Mesenchymal stem cell therapy for neurological disorders - Medipost

Alternative Names: Neurostem; Neurostem-AD

Latest Information Update: 22 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medipost
  • Class Antidementias; Mesenchymal stem cell therapies; Neural stem cell therapies; Neuroprotectants
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Alzheimer's disease
  • No development reported Amyotrophic lateral sclerosis; Stroke

Most Recent Events

  • 18 Mar 2022 Medipost completes a phase I/II follow-up trial for Alzheimer's disease in South Korea (NCT03172117)
  • 28 Feb 2022 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Intracerebral, Injection)
  • 12 Jul 2021 Samsung Medical Center plans a clinical trial for Alzheimer's Disease in South Korea (Intraventricular) (NCT04954534)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top